Patents by Inventor Robert McKay

Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6316259
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 alpha. Methods of using these compounds for modulation of glycogen synthase kinase 3 alpha expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 alpha are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: November 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert McKay, Madeline M. Butler, Jacqueline Wyatt
  • Patent number: 6312900
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of Activating Protein 1 (AP-1) expression are provided. In accordance with various embodiments of the present invention, oligonucleotides are provided which are specifically hybridizable with c-fos or c-jun, the genes encoding c-Fos or c-Jun, respectively. In a preferred embodiment, a method of modulating the metastasis of malignant tumors via modulation of one or more of the AP-1 subunits is provided; this method can be effected using the oligonucleotides of the invention or any other agent which modulates AP-1 or AP-1-mediated transcription.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: November 6, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Robert McKay, Loren Miraglia, Brenda Baker
  • Patent number: 6300320
    Abstract: Methods and compositions are provided for modulating c-jun expression using inhibitors of PKC-&agr;. In preferred embodiments, the specific inhibitors are antisense oligonucleotides hybridizable to PKC-&agr;. In preferred embodiments, the oligonucleotides contain one or more chemical modifications.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: October 9, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Robert McKay
  • Patent number: 6284538
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: September 4, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Robert McKay
  • Patent number: 6221850
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: April 24, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela Scott Nero, William A. Gaarde
  • Patent number: 6210892
    Abstract: The present invention provides compositions and methods for controlling the behavior of a cell, tissue or organism through antisense modulation of mRNA processing, using antisense compounds which does not support cleavage of the mRNA target.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: April 3, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Stanley T. Cooke, Muthiah Manoharan, Jacqueline R. Wyatt, Brenda F. Baker, Brett P. Monia, Susan M. Freier, Robert McKay, James G. Karras
  • Patent number: 6187545
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Jacqueline Wyatt, Lex M. Cowsert
  • Patent number: 6159734
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Peroxisome proliferator-activated receptor gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Peroxisome proliferator-activated receptor gamma. Methods of using these compounds for modulation of Peroxisome proliferator-activated receptor gamma expression and for treatment of diseases associated with expression of Peroxisome proliferator-activated receptor gamma are provided.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: December 12, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Robert McKay, Alexander H. Borchers, Brenda F. Baker
  • Patent number: 6140124
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero, Robert McKay
  • Patent number: 6136603
    Abstract: Compositions and methods are provided for antisense modulation of interleukin-5 signal transduction. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding interleukin-5 and interleukin-5 receptor.alpha. are preferred. Methods of using these compounds for modulation of interleukin-5 signal transduction and for treatment of diseases associated with interleukin-5 signal transduction are also provided.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: October 24, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, James G. Karras, Robert McKay
  • Patent number: 6133246
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela S. Nero, William A. Gaarde
  • Patent number: 6030837
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-mitochondrial. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-mitochondrial. Methods of using these compounds for modulation of PEPCK-mitochondrial expression and for treatment of diseases associated with expression of PEPCK-mitochondrial are provided.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Lex M. Cowsert
  • Patent number: 5985558
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of Activating Protein 1 (AP-1) expression are provided. In accordance with various embodiments of the present invention, oligonucleotides are provided which are specifically hybridizable with c-fos or c-jun, the genes encoding c-Fos or c-Jun, respectively. In a preferred embodiment, a method of modulating the metastasis of malignant tumors via modulation of one or more of the AP-1 subunits is provided; this method can be effected using the oligonucleotides of the invention or any other agent which modulates AP-1 or AP-1-mediated transcription.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: November 16, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Robert McKay, Loren Miraglia, Brenda Baker
  • Patent number: 5877309
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: March 2, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Robert McKay, Nicholas M. Dean
  • Patent number: 5861748
    Abstract: A probe for a nuclear magnetic resonance spectrometer having improved sensitivity and efficiency is described, comprising an impedance matched and tuned coaxial transmission network, multiple radio frequency input-output connections, and a single sample coil. Each individual radio frequency input-output connector and its associated capacitive impedance matching and tuning circuitry is remotely disposed from the magnetic field of the spectrometer. Additional radio frequency input-output connectors of lower frequencies may be modularly added and removed from the probe without altering the impedance settings of high frequency connectors already present.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: January 19, 1999
    Inventors: Jacob Schaefer, Robert A. McKay
  • Patent number: 4449709
    Abstract: A game board having a plurality of spaces upon which a plurality of primary and secondary playing elements move. The structure of the primary elements is such that the secondary elements can be placed inside of them. In the center of the game board is placed a control device. The control device has a hingedly mounted spinner which controls the amount of movement of the playing elements. The control device further includes a means for ejecting the secondary elements from the primary elements.
    Type: Grant
    Filed: June 1, 1982
    Date of Patent: May 22, 1984
    Inventor: Robert McKay
  • Patent number: 4446431
    Abstract: A double-tuned single coil probe for a nuclear magnetic resonance spectrometer having improved sensitivity is described comprising a double-tuned circuit means in which the low frequency irradiation is fed to a transmission line through an inductor means. The double-tuned circuit means of the invention may be remotely disposed from the magnetic field which results in greater sensitivity.
    Type: Grant
    Filed: August 24, 1981
    Date of Patent: May 1, 1984
    Assignee: Monsanto Company
    Inventor: Robert A. McKay
  • Patent number: 4099125
    Abstract: A circuit for correcting frequency errors in an incoming signal that includes a particular frequency signal. The circuit includes dual phase locked loop circuitry for providing a frequency feedback control, detecting circuitry for detecting the presence of the particular coded signal and generating a hold signal, and a sample and hold circuitry disposed in the feedback path of the phase locked loop circuitry and responsive to the hold signal for setting the feedback control at a particular value to provide an optimal frequency error correction for the particular frequency signal and for holding the feedback control at the particular value for the entire spectrum of the incoming signal, whereby the frequency feedback control set for the particular frequency tone is used for the entire spectrum of the incoming signal to minimize the error in the output frequencies of the circuit.
    Type: Grant
    Filed: June 23, 1976
    Date of Patent: July 4, 1978
    Assignee: Motorola, Inc.
    Inventors: Robert McKay Bennett, Jr., James Leslie Osborn